IRVINE, Calif. and WOODLANDS,
Texas, March 2, 2011 /PRNewswire/ -- ChromaDex
Corporation (OTC Bulletin Board: CDXC), and Bruker Optics Inc., a
subsidiary of Bruker Corporation (Nasdaq: BRKR), announced today a
co-development and co-marketing agreement that will promote a new
approach to dietary supplement testing. The collaboration will
capitalize on the extensive phytochemical and botanical reference
standard capabilities of ChromaDex and will initially focus on the
near infrared spectrometer (NIR) technology created by Bruker
Optics. The parties anticipate extending the relationship to
include other Bruker analytical technologies.
Through this collaboration, a dietary supplement producer will
have the opportunity to obtain the in-house capabilities of a
contract laboratory without the associated start-up costs. The
system enables the manufacturer to not only quickly and accurately
perform raw material identity testing, but also to determine if any
adulteration has taken place. This new approach is accomplished by
existing staff utilizing a Bruker NIR unit located in the
manufacturer's facility.
"This novel approach to quality control testing will enable
manufacturers to save time and money, while at the same time
providing a robust solution to quality needs that will greatly
benefit the industry," said Frank
Jaksch, CEO and Co-Founder of ChromaDex, Inc. "We have
chosen to collaborate with Bruker on this because we believe the
testing platform they have developed, when coupled with our
products and knowledge, will prove to be the solution the market
has long been seeking."
"This collaboration has the potential to significantly advance
dietary supplement testing at the manufacturer's location," said
John Richmond, Vice President of
Bruker Optics Inc. "ChromaDex has the deep knowledge of cGMP
compliance and a leading reference standards library. We look
forward to working with the Company and anticipate extending this
collaboration to additional analytical equipment that will assist
dietary supplement producers to verify identity, adulteration,
quantitation and origin testing."
About ChromaDex
ChromaDex is a leader in the development of phytochemical and
botanical reference standards, as well as analytical tools and
services to meet product regulatory, quality, efficacy and safety
standards. ChromaDex discovers, develops and markets novel, natural
ingredients that fill unmet needs in the dietary supplement, food
and beverage, cosmetic or pharmaceutical markets. Through a
combination of licensed technology and its own R&D, ChromaDex
utilizes plants and natural products to develop innovative
ingredients. The company has an impressive pipeline of new
ingredients, including its pTeroPure™ pterostilbene on which it has
worldwide, exclusive patent rights. ChromaDex has initiated a
clinical study on this new product, pTeroPure™ pterostilbene
(http://www.pteropure.com/). For more information, visit
www.ChromaDex.com or follow ChromaDex on Twitter @ChromaDex.
About Bruker Corporation
Bruker Corporation is a leading provider of high-performance
scientific instruments and solutions for molecular and materials
research, as well as for industrial and applied analysis. For more
information about Bruker Corporation, please visit
www.bruker.com
ChromaDex Forward-Looking Statements
Any statements that are not historical facts contained in this
release are forward-looking statements. Actual results may differ
materially from those projected or implied in any forward-looking
statements. Such statements involve risks and uncertainties,
including but not limited to those relating to product and customer
demand, market acceptance of our products, the effect of economic
conditions both nationally and internationally, ability to protect
our intellectual property rights, impact of any litigation or
infringement actions brought against us, competition from other
providers and products, risks in product development, our ability
to raise capital to fund continuing operations, the ability to
complete transactions, and other factors discussed from time to
time in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by law.
CAUTIONARY STATEMENT OF BRUKER CORPORATION
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including, but not limited to, risks and
uncertainties relating to adverse changes in conditions in the
global economy and volatility in the capital markets, the
integration of businesses we have acquired or may acquire in the
future, changing technologies, product development and market
acceptance of our products, the cost and pricing of our products,
manufacturing, competition, dependence on collaborative partners
and key suppliers, capital spending and government funding
policies, changes in governmental regulations, realization of
anticipated benefits from economic stimulus programs, intellectual
property rights, litigation, and exposure to foreign currency
fluctuations and other risk factors discussed from time to time in
our filings with the Securities and Exchange Commission. These and
other factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our annual
report on Form 10-K for the year ended December 31, 2009, our most recent quarterly
reports on Form 10-Q and our current reports on Form 8-K. We
expressly disclaim any intent or obligation to update these
forward-looking statements other than as required by law.
Investor
Inquiries:
|
|
Liviakis Financial
Communications, Inc.
|
|
John M. Liviakis,
President
|
|
415-389-4670
|
|
John@Liviakis.com
|
|
|
|
ChromaDex Contact
|
|
Jenny Robles
|
|
Administrative Assistant to the
CEO and President
|
|
10005 Muirlands Blvd, Suite G,
Irvine, CA 92618
|
|
949-419-0288
|
|
jennyr@chromadex.com
|
|
|
|
Media Inquiries:
|
|
Megan Lavine
|
|
Canale Communications
|
|
4010 Goldfinch St., San Diego,
CA, 92103
|
|
619-849-5388
|
|
megan@canalecomm.com
|
|
|
|
Bruker Contact
|
|
Dr. Thorsten Thiel Bruker
BioSpin
|
|
Director of Marketing
Communications
|
|
+49 721-5161–6517
|
|
thorsten.thiel@bruker.com
|
|
|
SOURCE ChromaDex Corporation